

EPI Country Report

ANGUILLA, 2019



Demographics and socioeconomic

Total Population (in 1000) (2019)	17.76
Population <1 year of age (in 1000) (2019)	0.24
Population 1 year of age (in 1000)(2019)	0.27
Population <5 years of age (in 1000) (2019)	1.30
Women of childbearing age (2019)	8.71
Infant Mortality Rate (per 1000 live births) (2017)	20.70
Gross national income (US\$ per capita) current value (2018)	-
National Health Expenditure Public (2016)	-
National Health Expenditure Private (2016)	-

Immunization system highlights

- There is no comprehensive multi-year plan (MYP) for immunization.
- A standing national technical advisory group on immunization (NITAG) The group met 3 times in 2019.
- 98% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


Immunization Schedule

AIA	Doses					
	1	2	3	4	5	6
BCG	B					
HepB_Pediatric	B					
DTP-Hib						
DTP-Hib-HepB	2M	4M	6M			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV				18M	4-5YRS	
DTP						
IPV	2M	4M				
OPV			6M	18M	4-5yrs	15yrs
MMR	1yr	2yr				
Pneumoco_ conj	2M	4M	6M	18M		
Rotavirus						
Td					15YRS	
TdaP					4-5YRS	15YRS
HPV	1st contact	6M				

Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	1998
Hepatitis B	1997
HPV	2016
Influenza	2005
MMR1	1987
MMR2	
Pentavalent	2000
Pneumococcal Conjugate	
Rotavirus	
Tdap	
Tetraivalent DPT-Hib or DPT-HepB	
Yellow Fever	

Vaccination Coverage



Surveillance Indicators - AFP (CARPHA)


	2019
Number od AFP suspected cases	8
AFP rate per 100,000 population <15 years old	0.57
% of cases with 1 adequate samples	100
% of cases investigated within <48 hours	100
% sites reporting	83

Surveillance Indicators - MR (CARPHA)


	2019
Number of suspected cases	371
% of cases with adequate investigation	86
% of cases with adequate blood samples	98
% of samples received in laboratory <=5 days	9
% of laboratory samples results <=4 days	83




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend		
NB/nb-newborn	● with stockout	
M/m -month	● no stockout	
Y/y-year	● no data available	
WCBA-women of childbearing age		

Vaccine Stockout

